.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Identifying accurate predictors of recurrence in renal cell carcinoma (RCC) remains essential for personalized patient care. The GRANT score RCC prognosis model provides a streamlined method to stratify risk using four routinely available clinical factors: grade, age, nodal status, and tumor size. Consequently, this prospective external validation within the ECOG-ACRIN EA8143 PROSPER trial confirms its reliability for surgically treated patients.
The study analyzed 714 patients to determine the accuracy of the GRANT score in a modern trial setting. Specifically, researchers categorized patients into favorable (0\u20131 risk factors) and unfavorable (2\u20134 risk factors) groups. Results revealed that the favorable group achieved a significantly longer median relapse-free survival (RFS) of 61.1 months. In contrast, the unfavorable group reached only 36.9 months. Moreover, the hazard ratio for RFS was 0.36, highlighting a substantial difference in recurrence risk between groups.
The model demonstrated consistent discrimination with a C-index of 0.61 for RFS and 0.63 for overall survival (OS). Furthermore, because it relies on standard pathology and clinical data, this tool offers a practical alternative to more complex scoring systems. Therefore, clinicians can use these results to refine follow-up schedules and potentially select candidates for adjuvant therapies. Additionally, the GRANT score maintains its performance across different patient cohorts. However, practitioners should still integrate these findings with local guidelines. Consequently, the GRANT score remains a robust tool for routine urological oncology practice.
The GRANT score integrates four key factors: Fuhrman/ISUP grade, patient age, pathological nodal status, and pathological tumor size.
It classifies patients into favorable or unfavorable risk groups. This allows for tailored surveillance and informed discussions regarding the risk of relapse after surgery.
While primarily validated for clear-cell and papillary subtypes, this specific prospective analysis within the PROSPER trial further confirms its utility in a modern clinical cohort.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a substitute for professional healthcare. Refer to the latest local and national guidelines for clinical practice.
References
Buti S et al. A prospective external validation of the GRade, Age, Nodes and Tumor (GRANT) score in the ECOG-ACRIN EA8143 PROSPER trial. Oncologist. 2026 Feb 15. doi: undefined. PMID: 41693026.
Buti S et al. Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population. Ann Oncol. 2017;28(11):2747-2753.
Buti S et al. Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database. Sci Rep. 2019;9:13218.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A prospective validation study confirms the GRANT score's ability to stratify recurrence risk in renal cell carcinoma patients using routine clinical data....
6 months ago
Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
